Apogee Therapeutics (NASDAQ:APGE) Price Target Increased to $95.00 by Analysts at Stifel Nicolaus

Apogee Therapeutics (NASDAQ:APGEFree Report) had its price target hoisted by Stifel Nicolaus from $46.00 to $95.00 in a research report report published on Tuesday morning, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. BTIG Research started coverage on Apogee Therapeutics in a research note on Wednesday, December 20th. They set a buy rating and a $43.00 target price for the company. Guggenheim raised their price objective on Apogee Therapeutics from $44.00 to $91.00 and gave the stock a buy rating in a research report on Tuesday. Finally, Wedbush reissued an outperform rating and issued a $87.00 price objective (up from $40.00) on shares of Apogee Therapeutics in a research report on Tuesday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of Buy and an average target price of $71.83.

Check Out Our Latest Analysis on APGE

Apogee Therapeutics Trading Up 3.5 %

NASDAQ:APGE opened at $67.54 on Tuesday. The stock has a fifty day moving average price of $36.43 and a 200-day moving average price of $26.29. Apogee Therapeutics has a fifty-two week low of $14.19 and a fifty-two week high of $68.50.

Institutional Trading of Apogee Therapeutics

A number of large investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in Apogee Therapeutics in the 3rd quarter worth $105,000. Bank of New York Mellon Corp bought a new position in shares of Apogee Therapeutics during the third quarter valued at approximately $1,271,000. Strs Ohio bought a new stake in Apogee Therapeutics during the 3rd quarter valued at about $87,000. TD Asset Management Inc bought a new stake in Apogee Therapeutics during the 3rd quarter valued at about $677,000. Finally, Platinum Investment Management Ltd. bought a new stake in Apogee Therapeutics in the 3rd quarter worth about $6,042,000. Institutional investors own 32.06% of the company’s stock.

About Apogee Therapeutics

(Get Free Report)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Further Reading

Analyst Recommendations for Apogee Therapeutics (NASDAQ:APGE)

Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.